Compare iShares MSCI France ETF (EWQ) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.41M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 31× iShares MSCI France ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 57 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWQ | GMED | |
|---|---|---|
Market Cap | $330.41M | $10.25B |
Volume | 244,426 | 1,108,124 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $96.82 |
52-Week Low | $41.24 | $58.33 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.63, up 0.95% with a bearish technical signal from moving averages. The stock faces European market pressures including ECB rate hikes and energy-driven inflation concerns. Key support sits at $41 with resistance at $42, while RSI indicators show mixed signals between neutral and oversold conditions.
European economic uncertainty and monetary tightening create headwinds, though Goldman Sachs notes resilience in European equities. The stock's technical weakness suggests cautious near-term positioning amid macroeconomic volatility in eurozone markets.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
